Search

Your search keyword '"GENTILE, MASSIMO"' showing total 1,340 results
Start Over Author "GENTILE, MASSIMO"
1,340 results on '"GENTILE, MASSIMO"'

1. Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience

Author

Mele, Giuseppe, Derudas, Daniele, Conticello, Concetta, Barilà, Gregorio, Gentile, Massimo, Rocco, Stefano, Palmieri, Salvatore, Palazzo, Giulia, Germano, Candida, Reddiconto, Giovanni, Sgherza, Nicola, De Novellis, Danilo, Galeone, Carlotta, Castiglioni, Sara Agavni’, Deiana, Luca, Pascarella, Anna, Martino, Enrica Antonia, Foggetti, Ilaria, Blasi, Ilenia, Spina, Alessandro, Di Renzo, Nicola, Maggi, Alessandro, Tarantini, Giuseppe, Di Raimondo, Francesco, Specchia, Giorgina, Musto, Pellegrino, and Pastore, Domenico

Published
2024
Full Text
View/download PDF

2. Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study

Author

Leotta, Salvatore, Markovic, Uros, Duminuco, Andrea, Mulè, Antonino, Porretto, Ferdinando, Federico, Vincenzo, Gentile, Massimo, Pastore, Domenico, Nigro, Luca Lo, Selleri, Carmine, Serio, Bianca, Calafiore, Valeria, Patti, Caterina, Mauro, Elisa, Vetro, Calogero, Maugeri, Cinzia, Parisi, Marina, Fiumara, Paolo, Parrinello, Laura, Marino, Sara, Scuderi, Grazia, Garibaldi, Bruno, Musso, Maurizio, Renzo, Nicola Di, Vigna, Ernesto, Martino, Enrica Antonia, Raimondo, Francesco Di, and Milone, Giuseppe

Published
2024
Full Text
View/download PDF

5. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

Author

Botta, Cirino, Perez, Cristina, Larrayoz, Marta, Puig, Noemi, Cedena, Maria-Teresa, Termini, Rosalinda, Goicoechea, Ibai, Rodriguez, Sara, Zabaleta, Aintzane, Lopez, Aitziber, Sarvide, Sarai, Blanco, Laura, Papetti, Daniele M., Nobile, Marco S., Besozzi, Daniela, Gentile, Massimo, Correale, Pierpaolo, Siragusa, Sergio, Oriol, Albert, González-Garcia, Maria Esther, Sureda, Anna, de Arriba, Felipe, Rios Tamayo, Rafael, Moraleda, Jose-Maria, Gironella, Mercedes, Hernandez, Miguel T., Bargay, Joan, Palomera, Luis, Pérez-Montaña, Albert, Goldschmidt, Hartmut, Avet-Loiseau, Hervé, Roccaro, Aldo, Orfao, Alberto, Martinez-Lopez, Joaquin, Rosiñol, Laura, Lahuerta, Juan-José, Blade, Joan, Mateos, Maria-Victoria, San-Miguel, Jesús F., Martinez Climent, Jose-Angel, and Paiva, Bruno

Published
2023
Full Text
View/download PDF

6. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

Author

Bomben, Riccardo, Rossi, Francesca Maria, Vit, Filippo, Bittolo, Tamara, Zucchetto, Antonella, Papotti, Robel, Tissino, Erika, Pozzo, Federico, Degan, Massimo, Polesel, Jerry, Bulian, Pietro, Marasca, Roberto, Reda, Gianluigi, Laurenti, Luca, Olivieri, Jacopo, Chiarenza, Annalisa, Laureana, Roberta, Postorino, Massimiliano, Del Principe, Maria Ilaria, Cuneo, Antonio, Gentile, Massimo, Morabito, Fortunato, Fronza, Gilberto, Tafuri, Agostino, Zaja, Francesco, Foà, Robin, Di Raimondo, Francesco, Del Poeta, Giovanni, and Gattei, Valter

Published
2023
Full Text
View/download PDF

7. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial

Author

Mazzucconi, Maria Gabriella, Rodeghiero, Francesco, Avvisati, Giuseppe, De Stefano, Valerio, Gugliotta, Luigi, Ruggeri, Marco, Vianelli, Nicola, Fazi, Paola, Paoloni, Francesca, Sargentini, Valeria, Baldacci, Erminia, Ferretti, Antonietta, Martino, Bruno, Vincelli, Iolanda Donatella, Carli, Giuseppe, Fortuna, Stefania, Di Ianni, Mauro, Ranalli, Paola, Palandri, Francesca, Polverelli, Nicola, Lugli, Elisabetta, Rivolti, Elena, Patriarca, Andrea, Rago, Angela, D’Adda, Mariella, Gentile, Massimo, Siragusa, Sergio, Sibilla, Silvia, Carella, Angelo Michele, Rossi, Elena, Battistini, Roberta, Zaja, Francesco, Bocchia, Monica, Di Renzo, Nicola, Musto, Pellegrino, Crugnola, Monica, Giuffrida, Anna Chiara, Krampera, Mauro, Tafuri, Agostino, and Santoro, Cristina

Published
2024
Full Text
View/download PDF

8. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing

Author

Oliva, Stefania, Genuardi, Elisa, Paris, Laura, D'Agostino, Mattia, Rogers, Jennifer, Rota-Scalabrini, Delia, Jacob, Allison P., Patriarca, Francesca, Luppi, Mario, Bertazzoni, Paola, Velluti, Cristina, Capra, Andrea, Saraci, Elona, Rossi, Marco, Allegra, Alessandro, Mina, Roberto, Gentile, Massimo, Kirsch, Ilan R., Belotti, Angelo, Cavo, Michele, Bruno, Benedetto, Musto, Pellegrino, Boccadoro, Mario, Zamagni, Elena, and Gay, Francesca

Published
2023
Full Text
View/download PDF

10. The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia

Author

Bruzzese, Antonella, primary, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Stanzione, Gaia, additional, Zimbo, Annamaria, additional, Lugli, Elisabetta, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

11. Momelotinib in myelofibrosis

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Zimbo, Annamaria, additional, Fragliasso, Valentina, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

12. MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells

Author

Matis, Serena, Grazia Recchia, Anna, Colombo, Monica, Cardillo, Martina, Fabbi, Marina, Todoerti, Katia, Bossio, Sabrina, Fabris, Sonia, Cancila, Valeria, Massara, Rosanna, Reverberi, Daniele, Emionite, Laura, Cilli, Michele, Cerruti, Giannamaria, Salvi, Sandra, Bet, Paola, Pigozzi, Simona, Fiocca, Roberto, Ibatici, Adalberto, Angelucci, Emanuele, Gentile, Massimo, Monti, Paola, Menichini, Paola, Fronza, Gilberto, Torricelli, Federica, Ciarrocchi, Alessia, Neri, Antonino, Fais, Franco, Tripodo, Claudio, Morabito, Fortunato, Ferrarini, Manlio, and Cutrona, Giovanna

Published
2022
Full Text
View/download PDF

13. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Author

Antic, Darko, Milic, Natasa, Chatzikonstantinou, Thomas, Scarfò, Lydia, Otasevic, Vladimir, Rajovic, Nina, Allsup, David, Alonso Cabrero, Alejandro, Andres, Martin, Baile Gonzales, Monica, Capasso, Antonella, Collado, Rosa, Cordoba, Raul, Cuéllar-García, Carolina, Correa, Juan Gonzalo, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Dimou, Maria, Doubek, Michael, Efstathopoulou, Maria, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Lopez-Garcia, Alberto, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, da Silva, Maria Gomes, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga B., Kalicińska, Elżbieta, Kater, Arnon P., Kersting, Sabina, Koren-Michowitz, Maya, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Fresa, Alberto, Levin, Mark-David, Mayor Bastida, Carlota, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Nunes, Raquel, Olivieri, Jacopo, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Reda, Gianluigi, Rigolin, Gian Matteo, Shrestha, Amit, Šimkovič, Martin, Smirnova, Svetlana, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Te Raa, Doreen, Tomic, Kristina, Tonino, Sanne, Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Vukovic, Vojin, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, Segundo, Lucrecia Yáñez San, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Carrier, Marc, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2022
Full Text
View/download PDF

14. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

Author

Botta, Cirino, Maia, Catarina, Garcés, Juan-José, Termini, Rosalinda, Perez, Cristina, Manrique, Irene, Burgos, Leire, Zabaleta, Aintzane, Alignani, Diego, Sarvide, Sarai, Merino, Juana, Puig, Noemi, Cedena, María-Teresa, Rossi, Marco, Tassone, Pierfrancesco, Gentile, Massimo, Correale, Pierpaolo, Borrello, Ivan, Terpos, Evangelos, Jelinek, Tomas, Paiva, Artur, Roccaro, Aldo, Goldschmidt, Hartmut, Avet-Loiseau, Hervé, Rosinol, Laura, Mateos, Maria-Victoria, Martinez-Lopez, Joaquin, Lahuerta, Juan-José, Bladé, Joan, San-Miguel, Jesús F., and Paiva, Bruno

Published
2022
Full Text
View/download PDF

15. Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.

Author

Urso, Antonio, Martino, Enrica Antonia, Cuneo, Antonio, Gentile, Massimo, and Rigolin, Gian Matteo

Subjects
THERAPEUTIC use of antineoplastic agents, CHRONIC lymphocytic leukemia, GENOMICS, IMMUNOGLOBULINS, TREATMENT effectiveness, KARYOTYPES, BIOMARKERS
Abstract

Simple Summary: The treatment of chronic lymphocytic leukemia (CLL) has dramatically changed following the availability of new drugs with targeted mechanisms of action. Traditional and new prognostic factors are being investigated to individualize and guide these new treatments. In this review, we discuss the clinical relevance of genomic factors including immunoglobulin heavy chain variable (IGHV) mutational status, TP53 abnormalities, complex karyotype, and prognostic scores in relation to new targeted agents. Novel drugs have profoundly changed the outcomes in chronic lymphocytic leukemia (CLL) patients, and the traditional prognostic factors that were identified in the era of chemoimmunotherapy need to be validated in the context of these new targeted therapies. Currently, the most important prognostic genetic biomarkers are the immunoglobulin heavy chain variable (IGHV) mutational status, genetic aberrations including del(17p)/TP53 abnormalities, and the complex karyotype. In this review, we discuss the prognostic role of these genomic markers in relation to novel treatments. Moreover, we present and discuss new scoring systems that were elaborated and validated in the era of new drugs. In routine clinical practice, the application of an extensive genomic work-up with validated prognostic markers could improve the identification of "very high-risk" CLL patients who could benefit from novel, more effective targeted treatments. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfò, Lydia, Karakatsoulis, Georgios, Allsup, David, Cabrero, Alejandro Alonso, Andres, Martin, Antic, Darko, Baile, Mónica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuéllar-García, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Fürstenau, Moritz, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, Glenthøj, Andreas, Gomes da Silva, Maria, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Оlga B., Kalicińska, Elżbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Šimkovič, Martin, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, San Segundo, Lucrecia Yáñez, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, and Ghia, Paolo

Published
2021
Full Text
View/download PDF

18. Selinexor in multiple myeloma

Author

Martino, Enrica Antonia, primary, Vigna, Ernesto, additional, Bruzzese, Antonella, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Zimbo, Annamaria, additional, Torricelli, Federica, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

19. Impact of minimal residual disease response and of status of disease on survival after Blinatumomab in B-Cell Acute Lymphoblastic Leukemia: results from a Real-Life Study. Running title: MRD-response and Disease Status correlate with survival after Blinatumomab in ALL-B patients

Author

Leotta, Salvatore, primary, Markovic, Uros, additional, Duminuco, Andrea, additional, Mulè, Antonino, additional, Porretto, Ferdinando, additional, Federico, Vincenzo, additional, Gentile, Massimo, additional, Pastore, Domenico, additional, Nigro, Luca Lo, additional, Selleri, Carmine, additional, Serio, Bianca, additional, Calafiore, Valeria, additional, Patti, Caterina, additional, Mauro, Elisa, additional, Vetro, Calogero, additional, Maugeri, Cinzia, additional, Parisi, Marina, additional, Fiumara, Paolo, additional, Parrinello, Laura, additional, Marino, Sara, additional, Scuderi, Grazia, additional, Garibaldi, Bruno, additional, Musso, Maurizio, additional, Renzo, Nicola Di, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Raimondo, Francesco Di, additional, and Milone, Giuseppe, additional

Published
2024
Full Text
View/download PDF

22. Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

23. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort

Author

Martino, Enrica Antonia, primary, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Laurenti, Luca, additional, Visentin, Andrea, additional, Frustaci, Annamaria, additional, Vigna, Ernesto, additional, Pepe, Sara, additional, Catania, Gioacchino, additional, Loseto, Giacomo, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Sportoletti, Paolo, additional, Del Principe, Maria Ilaria, additional, Laureana, Roberta, additional, Coscia, Marta, additional, Galimberti, Sara, additional, Ferretti, Eleonora, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Polesel, Jerry, additional, Tedeschi, Alessandra, additional, Rossi, Davide, additional, Trentin, Livio, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

24. Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety

Author

Martino, Massimo, Naso, Virginia, Porto, Gaetana, Paviglianiti, Annalisa, Ferreri, Anna, Loteta, Barbara, Moscato, Tiziana, Console, Giuseppe, Gentile, Massimo, Rossi, Marco, Provenzano, Pasquale Fabio, Gori, Mercedes, Pitino, Anna Lisa, Morabito, Antonella, and Tripepi, Giovanni

Published
2020
Full Text
View/download PDF

25. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Author

Passamonti, Francesco, Cattaneo, Chiara, Arcaini, Luca, Bruna, Riccardo, Cavo, Michele, Merli, Francesco, Angelucci, Emanuele, Krampera, Mauro, Cairoli, Roberto, Della Porta, Matteo Giovanni, Fracchiolla, Nicola, Ladetto, Marco, Gambacorti Passerini, Carlo, Salvini, Marco, Marchetti, Monia, Lemoli, Roberto, Molteni, Alfredo, Busca, Alessandro, Cuneo, Antonio, Romano, Alessandra, Giuliani, Nicola, Galimberti, Sara, Corso, Alessandro, Morotti, Alessandro, Falini, Brunangelo, Billio, Atto, Gherlinzoni, Filippo, Visani, Giuseppe, Tisi, Maria Chiara, Tafuri, Agostino, Tosi, Patrizia, Lanza, Francesco, Massaia, Massimo, Turrini, Mauro, Ferrara, Felicetto, Gurrieri, Carmela, Vallisa, Daniele, Martelli, Maurizio, Derenzini, Enrico, Guarini, Attilio, Conconi, Annarita, Cuccaro, Annarosa, Cudillo, Laura, Russo, Domenico, Ciambelli, Fabrizio, Scattolin, Anna Maria, Luppi, Mario, Selleri, Carmine, Ortu La Barbera, Elettra, Ferrandina, Celestino, Di Renzo, Nicola, Olivieri, Attilio, Bocchia, Monica, Gentile, Massimo, Marchesi, Francesco, Musto, Pellegrino, Federici, Augusto Bramante, Candoni, Anna, Venditti, Adriano, Fava, Carmen, Pinto, Antonio, Galieni, Piero, Rigacci, Luigi, Armiento, Daniele, Pane, Fabrizio, Oberti, Margherita, Zappasodi, Patrizia, Visco, Carlo, Franchi, Matteo, Grossi, Paolo Antonio, Bertù, Lorenza, Corrao, Giovanni, Pagano, Livio, and Corradini, Paolo

Published
2020
Full Text
View/download PDF

27. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Author

Gentile, Massimo, Morabito, Fortunato, Del Poeta, Giovanni, Mauro, Francesca Romana, Reda, Gianluigi, Sportoletti, Paolo, Laurenti, Luca, Coscia, Marta, Herishanu, Yair, Recchia, Anna Grazia, Varettoni, Marzia, Murru, Roberta, Chiarenza, Annalisa, Condoluci, Adalgisa, Moia, Riccardo, Pietrasanta, Daniela, Loseto, Giacomo, Consoli, Ugo, Scortechini, Ilaria, Rossi, Francesca Maria, Zucchetto, Antonella, Fraticelli, Vincenzo, Vigna, Ernesto, Botta, Cirino, Tripepi, Giovanni, Arrigo, Graziella D’, Rago, Angela, Angeletti, Ilaria, Biagi, Annalisa, Del Giudice, Ilaria, Bomben, Riccardo, Rigolin, Gian Matteo, Rossi, Davide, Di Raimondo, Francesco, Gaidano, Gianluca, Polliack, Aaron, Cuneo, Antonio, Foà, Robin, and Gattei, Valter

Published
2021
Full Text
View/download PDF

28. Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment—67 Patients Multicenter Analysis.

Author

Charliński, Grzegorz, Steinhardt, Maximilian, Rasche, Leo, Gonzalez-Calle, Veronica, Peña, Camila, Parmar, Harsh, Wiśniewska-Piąty, Katarzyna, Dávila Valls, Julio, Olszewska-Szopa, Magdalena, Usnarska-Zubkiewicz, Lidia, Gozzetti, Alessandro, Ciofini, Sara, Gentile, Massimo, Zamagni, Elena, Kurlapski, Michał, Legieć, Wojciech, Vesole, David H., and Jurczyszyn, Artur

Subjects
CARDIAC amyloidosis, IMMUNOGLOBULIN light chains, SYMPTOMS, TREATMENT effectiveness, RETROSPECTIVE studies, MULTIVARIATE analysis, RESEARCH, MEDICAL records, ACQUISITION of data, CONFIDENCE intervals, OVERALL survival, PROPORTIONAL hazards models
Abstract

Simple Summary: Light-chain amyloidosis (AL) is a rare multisystem disorder. One of the most common organs involved in AL is the heart. We conducted a multi-center, retrospective analysis of 67 patients with the European 2012 modification of Mayo 2004 stage III cardiac AL. The prognosis of patients with advanced cardiac amyloidosis is poor. The median OS for the entire group was 35 months (95% CI: 7–67). The most important prognostic factors with the most significant impact on OS improvement in patients with modified Mayo stage III cardiac AL identified by multivariate Cox analysis are ECOG PS ≤ 1, NYHA FC ≤ 2, and achieving hematological response ≥ VGPR and cardiac response ≥ PR after first-line treatment. Light-chain amyloidosis (AL) is a rare multisystem disorder characterized by the deposition of misfolded amyloid fibrils derived from monoclonal immunoglobulin light chains in various organs. One of the most common organs involved in AL is the heart, with 50–70% of patients clinically symptomatic at diagnosis. We conducted a multi-center, retrospective analysis of 67 patients diagnosed between July 2012 and August 2022 with the European 2012 modification of Mayo 2004 stage III cardiac AL. The most important factors identified in the univariate Cox analysis contributing to a longer OS included Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1, New York Heart Association functional classification (NYHA FC) ≤ 2, the use of autologous stem cell transplantation (ASCT) after induction treatment, achieving a hematological response (≥very good partial response) and cardiac (≥partial response) response after first-line treatment. The most important prognostic factors with the most significant impact on OS improvement in patients with modified Mayo stage III cardiac AL identified by multivariate Cox analysis are ECOG PS ≤ 1, NYHA FC ≤ 2, and achieving hematological response ≥ VGPR and cardiac response ≥ PR after first-line treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Ivosidenib in acute myeloid leukemia

Author

Bruzzese, Antonella, primary, Labanca, Caterina, additional, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Imovilli, Annalisa, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

31. Teclistamab‐cqyv in multiple myeloma

Author

Martino, Enrica Antonia, primary, Bruzzese, Antonella, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

32. Tagraxofusp in myeloid malignancies

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Imovilli, Annalisa, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

33. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study

Author

Malfona, Francesco, primary, Tanasi, Ilaria, additional, Piccini, Matteo, additional, Papayannidis, Cristina, additional, Federico, Vincenzo, additional, Mancini, Valentina, additional, Roncoroni, Elisa, additional, Todisco, Elisabetta, additional, Bianchi, Simona, additional, Ciotti, Giulia, additional, Chiusolo, Patrizia, additional, Gentile, Massimo, additional, Gianfelici, Valentina, additional, Giglio, Fabio, additional, Malagola, Michele, additional, Mulé, Antonino, additional, Saraceni, Francesco, additional, Vetro, Calogero, additional, Zallio, Francesco, additional, Cappelli, Luca Vincenzo, additional, Pizzolo, Giovanni, additional, Foà, Robin, additional, Bonifacio, Massimiliano, additional, and Chiaretti, Sabina, additional

Published
2023
Full Text
View/download PDF

34. Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi

Author

Merli, Michele, Luminari, Stefano, Farina, Lucia, Cocito, Federica, Defrancesco, Irene, Gini, Guido, Arcari, Annalisa, Scapinello, Greta, Gentile, Massimo, Goldaniga, Maria, Loseto, Giacomo, Cencini, Emanuele, Greco, Antonino, Molinari, Anna Lia, Ferrario, Andrea, Bianchi, Benedetta, Mora, Barbara, Bertù, Lorenza, Saturni, Vincenzo, Bergamini, Fabio, Fabbri, Nicole, Rossi, Francesca Gaia, Bolis, Silvia, Passamonti, Francesco, and Arcaini, Luca

Published
2020
Full Text
View/download PDF

35. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Author

Scarfò, Lydia, Chatzikonstantinou, Thomas, Rigolin, Gian Matteo, Quaresmini, Giulia, Motta, Marina, Vitale, Candida, Garcia-Marco, Jose Antonio, Hernández-Rivas, José Ángel, Mirás, Fatima, Baile, Mónica, Marquet, Juan, Niemann, Carsten U., Reda, Gianluigi, Munir, Talha, Gimeno, Eva, Marchetti, Monia, Quaglia, Francesca Maria, Varettoni, Marzia, Delgado, Julio, Iyengar, Sunil, Janssens, Ann, Marasca, Roberto, Ferrari, Angela, Cuéllar-García, Carolina, Itchaki, Gilad, Špaček, Martin, De Paoli, Lorenzo, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Mauro, Francesca R., Šimkovič, Martin, Van Der Spek, Ellen, Vandenberghe, Elisabeth, Trentin, Livio, Wasik-Szczepanek, Ewa, Ruchlemer, Rosa, Bron, Dominique, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Farina, Lucia, Foglietta, Myriam, Gentile, Massimo, Herishanu, Yair, Herold, Tobias, Jaksic, Ozren, Kater, Arnon P., Kersting, Sabina, Malerba, Lara, Orsucci, Lorella, Popov, Viola Maria, Sportoletti, Paolo, Yassin, Mohamed, Pocali, Barbara, Barna, Gabor, Chiarenza, Annalisa, dos Santos, Gimena, Nikitin, Eugene, Andres, Martin, Dimou, Maria, Doubek, Michael, Enrico, Alicia, Hakobyan, Yervand, Kalashnikova, Olga, Ortiz Pareja, Macarena, Papaioannou, Maria, Rossi, Davide, Shah, Nimish, Shrestha, Amit, Stanca, Oana, Stavroyianni, Niki, Strugov, Vladimir, Tam, Constantine, Zdrenghea, Mihnea, Coscia, Marta, Stamatopoulos, Kostas, Rossi, Giuseppe, Rambaldi, Alessandro, Montserrat, Emili’, Foà, Robin, Cuneo, Antonio, and Ghia, Paolo

Published
2020
Full Text
View/download PDF

36. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Author

Frigeni, Marco, Besson, Caroline, Visco, Carlo, Fontaine, Helene, Goldaniga, Maria, Visentini, Marcella, Pulsoni, Alessandro, Torres, Harrys A., Peveling-Oberhag, Jan, Rossotti, Roberto, Zaja, Francesco, Rigacci, Luigi, Merli, Michele, Dorival, Céline, Alric, Camille, Piazza, Francesco, Gentile, Massimo, Ferrari, Angela, Pirisi, Mario, Nassi, Luca, Rattotti, Sara, Frustaci, Annamaria, Milella, Michele, Cencini, Emanuele, Defrancesco, Irene, Ferretti, Virginia Valeria, Bruno, Raffaele, Hermine, Olivier, and Arcaini, Luca

Published
2020
Full Text
View/download PDF

37. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant

Author

Martino, Massimo, Gori, Mercedes, Tripepi, Giovanni, Recchia, Anna Grazia, Cimminiello, Michele, Provenzano, Pasquale Fabio, Naso, Virginia, Ferreri, Anna, Moscato, Tiziana, Console, Giuseppe, Loteta, Barbara, Gallo, Giuseppe Alberto, Gentile, Massimo, Innao, Vanessa, Rossi, Marco, Morabito, Antonella, Vincelli, Iolanda Donatella, Mannina, Donato, and Pitino, Annalisa

Published
2020
Full Text
View/download PDF

39. Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts

Author

Martino, Massimo, Gori, Mercedes, Moscato, Tiziana, Naso, Virginia, Ferreri, Anna, Provenzano, Fabio, Loteta, Barbara, Sanguedolce, Maria Cristina, Console, Giuseppe, Dattola, Antonia, Pucci, Giulia, Gentile, Massimo, Morabito, Antonella, Recchia, Anna Grazia, Tripepi, Giovanni, and Pitino, Annalisa

Published
2019
Full Text
View/download PDF

40. Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature

Author

Barbieri, Emiliano, Martino, Enrica Antonia, Rivolti, Elena, Quaresima, Micol, Vigna, Ernesto, Neri, Antonino, Morabito, Fortunato, and Gentile, Massimo

Abstract

ABSTRACTIntroductionGain/amplification of 1q (+1q) represents one of the most prevalent cytogenetic abnormalities (CAs) observed in multiple myeloma (MM). Historical studies predating the advent of anti-CD38 monoclonal antibodies (moAbs) implicated + 1q in poor prognoses, prompting its integration into novel staging systems. However, with the emergence of daratumumab and isatuximab, two pivotal anti-CD38 moAbs, the landscape of MM therapy has undergone a profound transformation.Areas coveredThis review encompasses a comprehensive analysis of diverse study methodologies, including observational investigations, clinical trials, meta-analyses, and real-world database analyses. By synthesizing these data sources, we aim to provide an overview of the current understanding of + 1q in the context of anti-CD38 moAbs therapies.Expert opinionDespite the paucity of available data, evidence suggests a potential mitigating effect of daratumumab on the adverse prognostic implications of + 1q. However, this benefit seems to diminish in patients harboring ≥ 4 copies or with concurrent high-risk CAs. On the other hand, isatuximab demonstrated promising outcomes in the relapsed-refractory setting for + 1q MM patients. Nevertheless, direct comparison between the two compounds is currently challenging. The current evidence firmly supports the integration of anti-CD38 moAb-based therapies as the standard of care for + 1q patients, pending further elucidation.

Published
2024
Full Text
View/download PDF

41. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study

Author

Levi, Shai, Bronstein, Yotam, Goldschmidt, Neta, Morabito, Fortunato, Ziv-Baran, Tomer, Del Poeta, Giovanni, Bairey, Osnat, Del Principe, Maria Ilaria, Fineman, Riva, Mauro, Francesca Romana, Gutwein, Odit, Reda, Gianluigi, Ruchlemer, Rosa, Sportoletti, Paolo, Laurenti, Luca, Shvidel, Lev, Coscia, Marta, Tadmor, Tamar, Varettoni, Marzia, Aviv, Ariel, Murru, Roberta, Braester, Andrei, Chiarenza, Annalisa, Visentin, Andrea, Pietrasanta, Daniela, Loseto, Giacomo, Zucchetto, Antonella, Bomben, Riccardo, Olivieri, Jacopo, Neri, Antonio, Rossi, Davide, Gaidano, Gianluca, Trentin, Livio, Foà, Robin, Cuneo, Antonio, Perry, Chava, Gattei, Valter, Gentile, Massimo, and Herishanu, Yair

Subjects
Settore MED/15
Published
2023

42. Teclistamab‐cqyv in multiple myeloma.

Author

Martino, Enrica Antonia, Bruzzese, Antonella, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Subjects
MULTIPLE myeloma, BISPECIFIC antibodies, PLASMA cells, PATIENT experience, DISEASE relapse, PLASMACYTOMA
Abstract

Multiple myeloma (MM) is an incurable neoplasm characterized by significant morbidity and mortality. Despite advances in treatment, MM patients eventually experienced a relapse of the disease. Penta‐drug refractory patients continue to be the hard core of relapsed/refractory (RR) settings. Teclistamab‐cqyv is a humanized IgG4 antibody and a bispecific BCMA‐director CD3 T‐cell engager. It recruits endogenous T cells, by targeting CD3 receptors expressed on their surface, resulting in their activation against BCMA, an antigen expressed by plasma cells. US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved Teclistamab‐cqyv in monotherapy for the treatment of RRMM patients who have received at least three prior therapies, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti‐CD38 monoclonal antibodies (MoAbs) and have demonstrated disease progression during the last therapy. Its effectiveness was demonstrated in a pivotal clinical trial where the overall response rate (ORR) reached 60%. Other clinical studies are currently ongoing to investigate the association of the bispecific antibody with novel drugs with encouraging preliminary results, especially in the setting of heavily pretreated patients. In this review, the authors will provide a comprehensive overview of the drug, including its mechanism of action, major clinical trials, and future perspectives. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. The Epidemiology of Anal Human Papillomavirus (HPV) in HIV-Positive and HIV-Negative Women and Men: A Ten-Year Retrospective Observational Study in Rome (Italy).

Author

Fracella, Matteo, Oliveto, Giuseppe, Roberto, Piergiorgio, Cinti, Lilia, Gentile, Massimo, Coratti, Eleonora, D'Ettorre, Gabriella, Cavallari, Eugenio Nelson, Romano, Francesco, Santinelli, Letizia, Maddaloni, Luca, Frasca, Federica, Scagnolari, Carolina, Antonelli, Guido, and Pierangeli, Alessandra

Subjects
PAPILLOMAVIRUSES, HUMAN papillomavirus, HIV-positive women, ANAL cancer, HIV-positive men, SCIENTIFIC observation
Abstract

Human papillomaviruses (HPVs) commonly infect the anogenital mucosa; most infections are transient, but a fraction of those caused by high-risk (HR) types persist and may lead to anogenital cancer. The epidemiology of HPV genotypes in anal infections in groups at different risk for anal cancer has not been well described in Italy. This retrospective study reports the results of HPV DNA testing and complete genotyping performed on anal swabs from 691 female and male patients attending proctology clinics in Rome during 2012–2021; one-third had repeated testing. Cumulative HPV positivity in 1212 anal swabs was approximately 60%, was not age related, and showed an increasing trend over the study period. HPV rates differed significantly by sex and HIV status: HIV-negative women had the lowest (43.6%) and HIV-positive men the highest (83.5%) HPV prevalence. HIV-positive men had more oncogenic HPV genotypes detected, more multiple infections, and the highest frequency of persistent infections. Two-thirds of all infections were vaccine-preventable. This study found that anal HPV infection rates are still elevated and even increasing in groups at low and high risk of developing anal cancer. Prevention programs need to be improved to reduce rates of anal infection in young women and men. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Tagraxofusp in myeloid malignancies.

Author

Bruzzese, Antonella, Martino, Enrica Antonia, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Imovilli, Annalisa, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Subjects
DIPHTHERIA toxin, RECOMBINANT molecules, INTERLEUKIN-3, ADP-ribosylation, DENDRITIC cells
Abstract

Tagraxofusp (or SL‐401) is a recombinant molecule composed of human interleukin‐3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). Tagraxofusp's most significant success has come from studies involving patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive disease that is usually refractory to conventional chemotherapy. Tagraxofusp had an acceptable safety profile and high efficacy in early phase I/II studies on patients with BPDCN. Another phase II study confirmed the good response rates, resulting in Food and Drugs Administration and European Medicine Agency approval of tagraxofusp for the treatment of BPDCN. Considering its high efficacy and its manageable safety profile, tagraxofusp has been suddenly explored in other myeloid malignancies with high expression of cell surface CD123, both in monotherapy or combination strategies. The triplet tagraxofusp‐azacytidine‐venetoclax appears to be of particular interest among these combinations. Furthermore, combination strategies may be used to overcome tagraxofusp resistance. The downregulation of DPH1 (diphthamide biosynthesis 1), the enzyme responsible for the conversion of histidine 715 on eEF2 to diphthamide, which is then the direct target of ADP ribosylation DT, is typically associated with this resistance phenomenon. It has been discovered that azacitidine can reverse DHP1 expression and restore sensitivity to tagraxofusp. In conclusion, the success of tagraxofusp in BPDCN paved the way for its application even in other CD123‐positive malignancies. Nowadays, several ongoing trials are exploring the use of tagraxofusp in different myeloid neoplasms. This review aims to summarize the actual role of tagraxofusp in BPDCN and other CD123‐positive myeloid malignancies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Author

Visentin, Andrea, primary, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Minga, Eva, additional, Chamou, Dimitra, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Antic, Darko, additional, Baile, Mónica, additional, Baliakas, Panagiotis, additional, Besikli‐Dimou, Sotiria, additional, Bron, Dominique, additional, Chatzileontiadou, Sofia, additional, Cordoba, Raul, additional, Correa, Juan‐Gonzalo, additional, Cuéllar‐García, Carolina, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Delgado, Julio, additional, Dimou, Maria, additional, Donaldson, David, additional, Catherwood, Mark, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, Eichhorst, Barbara, additional, Elashwah, Salma, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Frederiksen, Henrik, additional, Fürstenau, Moritz, additional, García‐Marco, José A., additional, García‐Serra, Rocío, additional, Collado, Rosa, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Glenthøj, Andreas, additional, da Silva, Maria Gomes, additional, Hakobyan, Yervand K., additional, Herishanu, Yair, additional, Hernández‐Rivas, José Ángel, additional, Herold, Tobias, additional, Innocenti, Idanna, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark‐David, additional, Lista, Enrico, additional, Lopez‐Garcia, Alberto, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca R., additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Niemann, Carsten U., additional, Rodrigues, Raquel Nunes, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Qvist, Kristian, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Tadmor, Tamar, additional, Capasso, Antonella, additional, Del Poeta, Giovanni, additional, Gutwein, Odit, additional, Karlsson, Linda Katharina, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Reda, Gianluigi, additional, Saghumyan, Gevorg, additional, Shrestha, Amit, additional, Te Raa, Doreen, additional, Tonino, Sanne H., additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, van Kampen, Roel, additional, Wasik‐Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Segundo, Lucrecia Yáñez San, additional, Yassin, Mohamed, additional, Pocali, Barbara, additional, Vandenberghe, Elisabeth, additional, Iyengar, Sunil, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Cuneo, Antonio, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2023
Full Text
View/download PDF

46. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

Author

Avivi, Irit, primary, Vesole, David H., additional, Davila-Valls, Julio, additional, Usnarska-Zubkiewicz, Lidia, additional, Olszewska-Szopa, Magdalena, additional, Milunovic, Vibor, additional, Baumert, Bartłomiej, additional, Osękowska, Bogumiła, additional, Kopińska, Anna, additional, Gentile, Massimo, additional, Puertas-Martinez, Borja, additional, Robak, Paweł, additional, Crusoe, Edvan, additional, Rodriguez-Lobato, Luis Gerardo, additional, Gajewska, Małgorzata, additional, Varga, Gergely, additional, Delforge, Michel, additional, Cohen, Yael, additional, Gozzetti, Alessandro, additional, Pena, Camila, additional, Shustik, Chaim, additional, Mikala, Gabor, additional, Zalac, Klara, additional, Alexander, H. Denis, additional, Barth, Peter, additional, Weisel, Katja, additional, Martínez-López, Joaquín, additional, Waszczuk-Gajda, Anna, additional, Krzystański, Mateusz, additional, and Jurczyszyn, Artur, additional

Published
2023
Full Text
View/download PDF

47. Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy

Author

Morabito, Fortunato, primary, Adornetto, Carlo, additional, Monti, Paola, additional, Amaro, Adriana, additional, Reggiani, Francesco, additional, Colombo, Monica, additional, Rodriguez-Aldana, Yissel, additional, Tripepi, Giovanni, additional, D’Arrigo, Graziella, additional, Vener, Claudia, additional, Torricelli, Federica, additional, Rossi, Teresa, additional, Neri, Antonino, additional, Ferrarini, Manlio, additional, Cutrona, Giovanna, additional, Gentile, Massimo, additional, and Greco, Gianluigi, additional

Published
2023
Full Text
View/download PDF

48. P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL

Author

Vit, Filippo, primary, Bittolo, Tamara, additional, Papotti, Robel, additional, Pozzo, Federico, additional, Zucchetto, Antonella, additional, Tissino, Erika, additional, Zaina, Eva, additional, Catarossi, Ilaria, additional, Laureana, Roberta, additional, Olivieri, Jacopo, additional, Bulian, Pietro, additional, Levato, Luciano, additional, D’arena, Giovanni, additional, Armiento, Daniele, additional, Zamò, Alberto, additional, Leich, Ellen, additional, Rosenwald, Andreas, additional, Arons, Evgeny, additional, J. Kreitman, Robert, additional, Gentile, Massimo, additional, Laurenti, Luca, additional, Zaja, Francesco, additional, Tafuri, Agostino, additional, Chiarenza, Annalisa, additional, Ilaria DEL Principe, Maria, additional, Gattei, Valter, additional, and Bomben, Riccardo, additional

Published
2023
Full Text
View/download PDF

49. PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.

Author

Innocenti, Idanna, primary, Mosca, Antonio, additional, Tomasso, Annamaria, additional, Galitzia, Andrea, additional, Scarfò, Lydia, additional, Galli, Eugenio, additional, Laureana, Roberta, additional, Benintende, Giulia, additional, Mattiello, Veronica, additional, Morelli, Francesca, additional, Chiriu, Sabrina, additional, Del Principe, Maria Ilaria, additional, Zamprogna, Giulia, additional, Gentile, Massimo, additional, Fabbri, Nicole, additional, Autore, Francesco, additional, Sportoletti, Paolo, additional, Fresa, Alberto, additional, Catania, Gioacchino, additional, Coscia, Marta, additional, Tedeschi, Alessandra, additional, Sanna, Alessandro, additional, Varettoni, Marzia, additional, Ghia, Paolo, additional, Murru, Roberta, additional, and Laurenti, Luca, additional

Published
2023
Full Text
View/download PDF

50. Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura

Author

Bruzzese, Antonella, primary, Vigna, Ernesto, additional, Terzi, Dario, additional, Greco, Sonia, additional, Martino, Enrica Antonia, additional, Vangeli, Valeria, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Labanca, Caterina, additional, Morelli, Rosellina, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Zinno, Francesco, additional, Mastroianni, Antonio, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results